Advocacy group Aroreretini Aotearoa, says the changes will improve productivity for the ADHD community, by almost 57-million-dollars. Chief medical officer David Hughes says it will streamline ...

Starting on 27 January, Auckland Anniversary Day, and running through to 9 March, Moana Auckland promises an action-packed ...

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

The drug buying agency will also remove the renewal criteria for people with ADHD and narcolepsy.

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

On the other hand, efforts to manage these costs through preauthorizations – reviewing certain treatments and procedures to confirm they are medically necessary prior to receiving services – have been ...

People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...

Neuren Pharmaceuticals Limited (AU:NEU) has released an update. Neuren Pharmaceuticals stands to gain financially as its partner, Acadia ...

By AUT Journalism Student Vivek Panchal The Government has announced it will increase funding for Pharmac, boosting ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...